Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2024-09-10 Capital/Financing Update
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Vicore Pharma beslutar om en företrädesemission motsvarande cirka 782 MSEK
Capital/Financing Update Classification · 98% confidence The document is a press release announcing that the Board of Directors of Vicore Pharma Holding AB has decided to conduct a rights issue ('företrädesemission') to raise approximately 782 MSEK. This action involves the issuance of new shares to existing shareholders and is explicitly related to financing activities (funding clinical trials and preparing for Phase 3). This clearly falls under the definition of 'Capital/Financing Update' (CAP). Although it mentions a prospectus will be published later, the core content is the decision and terms of the capital raise itself, not just the announcement of the report (RPA/RNS).
2024-09-10 Swedish
Vicore Pharma announces a rights issue of approximately SEK 782 million
Capital/Financing Update Classification · 98% confidence The document is an announcement titled "Vicore Pharma announces a rights issue of approximately SEK 782 million." It details the resolution by the Board of Directors to carry out a new issue of shares with preferential rights for existing shareholders. This action directly relates to fundraising, financing activities, and changes in the capital structure (issuing new shares). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions the AGM authorized the action, the core subject is the Rights Issue itself, not the AGM materials (AGM-R) or the resulting share change notification (SHA), but the financing event. Since the document is a detailed announcement describing the terms, use of proceeds, and commitments for the share issue, it is classified as CAP, not RPA or RNS, as it is the primary disclosure of the financing event.
2024-09-10 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Vicore Pharma Holding AB covering the period from April 1 to June 30, 2024. It contains comprehensive financial statements, management commentary (VD-ord), pipeline updates, and financial tables (income statement, cash flow, etc.). It is clearly a quarterly financial report, not an announcement of one, and contains substantive financial data. Q2 2024
2024-08-22 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report Apr 1-Jun 30, 2024' for Vicore Pharma Holding AB. It contains comprehensive financial statements, including income statements, balance sheets, and detailed management commentary on financial performance, research and development, and operational highlights for the second quarter. It is a full interim report, not an announcement or a summary, and meets the criteria for an Interim/Quarterly Report (IR). Q2 2024
2024-08-22 English
Ökning av antalet aktier och röster i Vicore Pharma
Share Issue/Capital Change Classification · 99% confidence The document is a short announcement from Vicore Pharma dated May 31, 2024, titled 'Ökning av antalet aktier och röster i Vicore Pharma' (Increase in the number of shares and votes in Vicore Pharma). It explicitly states that the number of shares and votes has increased due to the exercise of stock options and subsequent delivery of shares to a participant in an incentive program. This directly relates to changes in the company's share capital and total number of shares. This fits the definition of 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. Although it is a regulatory announcement, SHA is more specific than the general 'RNS' fallback. The document length is short (2854 chars) and it announces a specific corporate action related to capital structure.
2024-05-31 Swedish
Increase of number of shares and votes in Vicore Pharma
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces an 'Increase of number of shares and votes' due to the exercise of warrants and subsequent share delivery under an incentive program. It details the exact increase in shares (11,025) and the resulting total outstanding shares (111,734,004). This action directly relates to changes in the company's capital structure via the issuance of new shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). Although it involves warrants, the core event is the resulting share issuance, not a general financing round (CAP) or a buyback (POS). The document is a direct announcement, not a report publication announcement (RPA), as it contains the substantive information itself.
2024-05-31 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.